Who to call at Atossa Therapeutics, Inc., and when
Fundz watches for the moments Atossa Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Atossa Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Atossa Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Atossa Therapeutics, Inc.. With Fundz connected, it knows.
Atossa Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
atossatherapeutics.comAI Executive Summary
AI-powered analysis of 8-K filing content
Atossa Therapeutics appointed Mark Daniel as Chief Financial Officer and principal accounting officer, effective October 14, 2025, succeeding Heather Rees, who remains as a non-officer employee through November 15, 2025 to assist the transition. The change matters because it replaces the company's top finance and accounting executive and sets the new CFO's compensation.
Key Takeaways
Mark Daniel, age 49, takes over as CFO and principal accounting officer effective immediately, with prior finance roles at Bruker Spatial Biology (SVP Finance, 2017-2025) and Newyu/Numera (CFO, 2014-2
Heather Rees, the outgoing CFO, stays as a non-officer employee until November 15, 2025, which gives a short overlap period for the handover.
3 more takeaways
Related Filings (10)
10 more filings from Atossa Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Atossa Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.